CLAIMS

1. An oral pharmaceutical formulation comprising a milk thistle extract of silybin with a purity higher than 80%, phospholipids, sorbitol and carragenin, wherein the weight ratio between the amount of silybin and the amount of phospholipids is in the range of 1:1.50 and 1:2.

2. The oral pharmaceutical formulation according to claim 1 comprises a milk thistle extract comprises silybin having a purity higher than 85%.

3. The oral pharmaceutical formulation according to claim 1 or claim 2 wherein the phospholipids are phosphatidylcholine.

4. The oral pharmaceutical formulation according to any one of claims 1-3, wherein the milk thistle extract comprises silybin and phospholipids.

5. The oral pharmaceutical formulation according to any one of claims 1-4, wherein silybin is in the range from 4.5% (about 100 mg) to 9.5% (about 200mg), preferably from 6.8% to 7%, more preferably 6.9% (150 mg) with respect to the total amount of the formulation.

6. The oral pharmaceutical formulation according to any one of claims 1-5, wherein the amount of sorbitol is from 60 to 66%, preferably 65%, with respect to the total amount of the formulation.

7. The oral pharmaceutical formulation according to any one of claims 1-6, wherein the amount of carragenin is 2-3% with respect to the total amount of the formulation.

8. The oral pharmaceutical formulation according to any one of claims 1-7, wherein the oral pharmaceutical formulation comprises also excipients selected from the group consisting of flavour enhancers, sweeteners, gliding agents, pigment agents, flavourings colouring agents.

9. The oral pharmaceutical formulation according to any one of claims 1-8, wherein the oral formulation is a sachet.

10. An oral pharmaceutical formulation according to any one of claims 1-9 for use in the treatment of chronic liver damage from alcohol, drugs, toxic substances, metabolic causes and viruses.

11. Use of an oral pharmaceutical formulation according to any one of claims 1-9 in the manufacture of a medicament for the treatment of chronic liver damage from alcohol, drugs, toxic substances, metabolic causes and viruses.